Muedzo Wakakwana Kurapa Radiation Dermatitis muVarwere vane Kenza Yezamu

Lutris Pharma nhasi yazivisa kuti yapedza kunyoreswa kwechikamu chechipiri chechikamu 1/2 chekiriniki yekuyedzwa kwe lead compound, LUT014, yakashandiswa musoro, novel B-Raf inhibitor, yekurapa radiation-induced dermatitis (RD) muvarwere vane kenza yemazamu. Yepamusoro-mutsara data inotarisirwa muchikamu chechitatu che2022.

The randomized, double-blind, placebo-controlled controlled part two of the phase 1/2 study yakanyora nhamba yevarwere ve20 uye yakagadzirirwa kuongorora kushanda kweLUT014 inotungamirirwa nepamusoro muvarwere vekenza yemazamu vane RD. Varwere vakave vasina kurongeka muchiyero che1: 1 kuti vagamuchire inotungamirwa nepamusoro LUT014 kana placebo kwemazuva makumi maviri nemasere, ichiteverwa nemwedzi miviri yekutevera nguva.

Mhedziso yekutanga yechikamu chechipiri ndeye shanduko mukuomarara kwemwaranzi dermatitis zvichibva pakuzvizivisa wega Dermatology Life Quality Index (QoL) mibvunzo pamazuva gumi nemana. Mamiriro ekupedzisira anosanganisira shanduko mukuomarara kweradiation dermatitis yakavakirwa paDermatology QoL yemibvunzo uye chiitiko chekurapa-zvinomuka zviitiko zvakashata sekuongororwa neCommon Terminology Criteria for Adverse Events (CTCAE) giredhi rekero kubva pakutanga kusvika kumavhiki gumi nemaviri.

"Migumisiro yakasimba yakaonekwa kubva kuvarwere vasere muChikamu 1 chekuedza kweLUT014 kurapa RD, yakatipa humwe chivimbo mukukwanisa kwechirwere ichi uye yakatikurudzira kuti titange chikamu chechipiri, zvisati zvatarisira," akadaro Benjamin W. Corn, MD, Chief Medical Officer weLutris Pharma. “Pachine chidikanwi chikuru chisingakwaniriswe pakati pevarwere vane gomarara rezamu vanorwara neRD, avo parizvino vasina nzira dzekurapwa dzakatenderwa. LUT2 ine yakasarudzika nzira yezviito ine chinangwa chekuenzanisa kuparadzwa kwemasero ari muchikamu cheganda nekusimudzira kuwanda kwesero, zvichizokwanisa kudzoreredza mhedzisiro yeRD.

"Kunyoreswa kwemurwere wekupedzisira muchikamu chakapofumadzwa chechikamu chechipiri chechikamu chedu 1/2 chidzidzo chinotiunzira imwe nhanho mberi mukuvandudzwa kwekiriniki yeLUT014 sekurapa kweRD," akadaro Noa Shelach, Ph.D., Chief Executive Officer we Lutris Pharma. "Inofungidzirwa kuti inenge hafu yevarwere vegomarara vanorapwa neradiation therapy, gore negore, uye ruzhinji rwevarwere vegomarara rezamu, kunyanya, vanosangana neimwe nzira yeRD. Zvichienderana nemaitiro ekuita kweLUT014, isu tinotenda kuti LUT104 inogona kuve nekukanganisa kwakakosha pahuwandu hwevarwere. Tinotarisira kuzivisa data rakasimba kubva muyedzo iyi muchikamu chechitatu chegore rino. "